Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Eindhoven – page 28

452 clinical trials in Eindhoven, The Netherlands across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Eindhoven at a glance
452
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

452 trials in Eindhoven

Open in trial search

Burkitt's lymphoma

Not recruiting

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Malignant melanoma

Not recruiting

Study on Early Discontinuation of Nivolumab and Ipilimumab in Patients with Advanced Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Colitis ulcerative

Not recruiting

Study on Vedolizumab for Patients with Active Ulcerative Colitis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Alimentiv Inc.

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Cough

Not recruiting

Study on the Effects of Camlipixant in Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Camlipixant
  • Sponsor:Bellus Health Inc.

Study of dose reduction strategy for tyrosine kinase inhibitors (imatinib, ponatinib, bosutinib, nilotinib, dasatinib) in patients with chronic myeloid leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Radboud universitair medisch centrum Stichting

Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Obexelimab
  • Sponsor:Zenas Biopharma (USA) LLC

Oesophageal carcinoma

Not recruiting

Study of Nivolumab for Patients with Esophageal Cancer Undergoing Active Surveillance After Chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Study on the Safety and Effects of PDC*lung01 Vaccine with Pemetrexed or Pembrolizumab for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:PDC line pharma

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Eindhoven

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on advanced gastric cancer, acute myeloid leukemia, and melanoma. Studies include innovative imaging techniques and combination therapies targeting specific genetic mutations.

  • Gastric Cancer Treatment Studies
  • Novel Leukemia Therapies
  • Prostate Cancer Diagnostics

Research includes evaluation of PSMA-PET/CT scanning and personalized treatment approaches for various cancer types.

02 Neurological Disorders

Clinical investigations focusing on intracerebral hemorrhage, status epilepticus, and dementia. Studies aim to improve treatment outcomes for patients with various neurological conditions.

  • Post-Cardiac Arrest Care
  • Stroke Management
  • Dementia Behavior Treatment

Emphasis on developing targeted therapies and improving patient outcomes through personalized treatment approaches.

03 Endocrine and Metabolic Studies

Research targeting thyroid disorders and hormonal conditions. Studies evaluate new treatment approaches including radiofrequency ablation and hormone replacement therapies.

  • Thyroid Treatment Comparisons
  • Hormone Therapy Optimization
  • Metabolic Disease Management

Focus on comparing traditional and innovative treatment methods for better patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.